Taxes, fees take bite out of Medicaid DSH payments

Disproportionate-share hospitals (DSHs) couldn’t cover their total costs for treating Medicaid and uninsured patients in 2011 through Medicaid payments, after accounting for taxes and fees paid to local governments.

The analysis, published in the December 2016 issue of Health Affairs, found DSH and other supplemental Medicaid payments accounted for about 25 percent of total Medicaid payments made to those hospitals in 2011. Those facilities were paid, on average, 108 percent of their costs for treating Medicaid patients alone. When factoring in uninsured patients, the number fell to 89 percent.

Two other items, however, took a chunk out of those hospitals’ payments: provider-specific taxes and contributions to local governments that go into a state’s share of Medicaid funding.

According to the analysis, taxes reduced Medicaid payments for DSHs by 4 percent. Local government contributions, which are only made by public hospitals, cut payments by 7 percent.

Across states, there was wide variation in gross Medicaid payment levels and in the effects of provider contributions on net payments,” wrote the study’s lead author, Robert Nelb, senior analyst at the Medicaid and CHIP Payment and Access Commission, along with his coauthors. “Gross payments exceeded costs for Medicaid patients in 31 states. However, when we adjusted for provider taxes and local government contributions, we found that only two states made net payments that exceeded costs for both Medicaid and uninsured patients.”

That separation between gross and net payments should be addressed, even though the data used predates the Affordable Care Act, as uncompensated care under Medicaid may increase as more people are covered through the program.

“As Medicaid enrollment grows, and the program becomes an even larger payer of hospital services, it will be important to monitor changes in the need for and role of Medicaid supplemental payments,” Nelb and his coauthors wrote.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.